Drugs / AL-704
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02510248 | Jul → Nov 2015 | chronic hepatitis C virus infection | Alios Biopharma Inc. | Terminated | Missed primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2015-12-21 | Medivir | Results Medivir announces that development of the HCV nucleotide polymerase inhibitor AL-704 was terminated by Janssen medivir.com ↗
However its clinical antiviral activity in persons infected with HCV genotype 1 was insufficient to justify further clinical studies. |
All press releases naming this drug 2 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AL-704 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02510248 ↗ |
| Action | Inhibit | “JNJ-54257099 (also known as ALS-022704 or AL-704) is a hepatitis C virus (HCV) nonstructural (NS)5B inhibitor” NCT02510248 ↗ |
| Route | Oral | “orally administered anti-HCV therapeutic” NCT02510248 ↗ |